Review
Biochemistry & Molecular Biology
Adela Markota Cagalj, Branka Marinovic, Zrinka Bukvic Mokos
Summary: This review examines the evidence for emerging therapies targeting the main pro-inflammatory cytokines in Hidradenitis suppurativa (HS). The most promising biologics in phase III trials are anti-IL-17 antibodies, secukinumab, and bimekizumab. An anti-IL-1 biologic, bermekimab, is currently in phase II trials and shows encouraging results. However, the clinical efficacies of all new targeted therapies published up to this point are limited, and more studies are needed to evaluate the efficacy of biological therapies for HS.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Dermatology
Natalia Kirsten, Nicole Zander, Matthias Augustin
Summary: This study investigated the prevalence and cutaneous comorbidities of hidradenitis suppurativa in the German working population, finding a point prevalence of 0.3% and identifying non-inflammatory hidradenitis suppurativa-related lesions in 3.0% of individuals. Patients with hidradenitis suppurativa were significantly more likely to have acne vulgaris, psoriasis, and other skin conditions.
ARCHIVES OF DERMATOLOGICAL RESEARCH
(2021)
Review
Biochemistry & Molecular Biology
Federica Li Pomi, Laura Macca, Alfonso Motolese, Ylenia Ingrasciotta, Massimiliano Berretta, Claudio Guarneri
Summary: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease associated with a wide range of cancers, such as nonmelanoma skin cancer and hematologic malignancies. Squamous cell carcinoma (SCC) is considered the most common complication in long-standing HS. Cautious surveillance and active intervention are suggested for HS patients, especially those with multiple comorbidities or later onset of the disease.
Review
Dermatology
Kelsey R. van Straalen, John R. Ingram, Matthias Augustin, Christos C. Zouboulis
Summary: Research interest in Hidradenitis Suppurativa (HS) has grown rapidly, and several new scores and tools are being developed to address the limitations of current assessment methods. These new measures have the potential to become the primary outcome measures in HS clinical trials and practice.
EXPERIMENTAL DERMATOLOGY
(2022)
Review
Dermatology
Terri Shih, Katrina Lee, Justine R. Seivright, Devea R. De, Vivian Y. Shi, Jennifer L. Hsiao
Summary: This study systematically reviewed literature on the efficacy and tolerability of hyperhidrosis treatments in patients with hidradenitis suppurativa (HS). Results showed that botulinum toxin treatments improved HS severity, quality of life, and hyperhidrosis, while microwave-based energy devices may pose harm in HS patients. More prospective studies are needed to further examine the utility of these treatments in HS.
DERMATOLOGIC THERAPY
(2022)
Review
Biochemistry & Molecular Biology
Elisa Molinelli, Helena Gioacchini, Claudia Sapigni, Federico Diotallevi, Valerio Brisigotti, Giulio Rizzetto, Annamaria Offidani, Oriana Simonetti
Summary: Hidradenitis suppurativa (HS) is an immune-mediated inflammatory disorder characterized by nodules, abscesses, sinus tracts, and scars in intertriginous areas. It causes pain, malodorous secretion, and significantly decreases the quality of life. The pathogenesis is not fully understood, but follicular hyperkeratosis of the pilosebaceous apocrine unit is considered the primary event. Since the registration of Adalimumab in 2015, several cytokines have been implicated in the pathomechanism of HS, leading to intensified research on novel therapeutic targets for HS management.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Dermatology
Caden Ulschmid, Linda Serrano, Ruizhe Wu, Gretchen M. Roth, Olayemi Sokumbi
Summary: In the United States, there are significant disparities in the severity and outcomes of hidradenitis suppurativa (HS) among African Americans compared to other racial and ethnic groups. Further investigation and addressing of these disparities are necessary.
INTERNATIONAL JOURNAL OF DERMATOLOGY
(2023)
Review
Dermatology
Carlos Cuenca-Barrales, Trinidad Montero-Vilchez, Manuel Sanchez-Diaz, Antonio Martinez-Lopez, Juan Angel Rodriguez-Pozo, Pablo Diaz-Calvillo, Salvador Arias-Santiago, Alejandro Molina-Leyva
Summary: This study aimed to synthesize the available scientific evidence on intralesional (IL) treatments in hidradenitis suppurativa (HS). The results showed that corticosteroid injections and light-based therapies appear to be effective and safe for both acute inflammatory lesions and fistulas. However, more prospective studies with larger sample sizes and standardized outcomes are needed to provide further scientific evidence on the subject.
Article
Dermatology
Amit Garg, Neeta Malviya, Andrew Strunk, Shari Wright, Afsaneh Alavi, Raed Alhusayen, Ali Alikhan, Steven D. Daveluy, Isabelle Delorme, Noah Goldfarb, Wayne Gulliver, Iltefat Hamzavi, Tarannum Jaleel, Alexa B. Kimball, Joslyn S. Kirby, Mark G. Kirchhof, Janice Lester, Hadar Lev-Tov, Michelle A. Lowes, Robert Micheletti, Lauren A. Orenstein, Vincent Piguet, Christopher Sayed, Jerry Tan, Haley B. Naik
Summary: This study aims to provide evidence-based screening recommendations for comorbidities associated with HS. Screening recommendations were made based on the consistency and quality of existing studies, disease prevalence and magnitude of association, as well as benefits, harms, and feasibility of screening. A total of 30 comorbidities were recommended for screening in order to improve patients' quality of life and health status.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2022)
Review
Dermatology
Dillon Mintoff, Farida Benhadou, Nikolai P. Pace, John W. Frew
Summary: Patients with Hidradenitis suppurativa often meet the criteria for a diagnosis of metabolic syndrome, leading to the need for multidisciplinary care. This paper reviews the inflammatory pathways in both conditions and evaluates how they may explain the risk of comorbid disease.
INTERNATIONAL JOURNAL OF DERMATOLOGY
(2022)
Article
Dermatology
Shari Wright, Andrew Strunk, Amit Garg
Summary: The prevalence of depression is higher among children, adolescents, and adults with HS compared to controls, indicating the need for periodic screening for depression.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2022)
Article
Dermatology
Nouf Almuhanna, Sheldon W. Tobe, Raed Alhusayen
Summary: There is a higher risk of chronic kidney disease (CKD) in patients with hidradenitis suppurativa (HS), especially in those who are aged 60 or older, male, obese, diabetic, hyperlipidemic, or have cardiovascular diseases. The prevalence of CKD in HS patients is 6.3%, higher than the 4.3% in non-HS controls. Early diagnosis and assessment of CKD in HS patients is important to prevent further progression.
Article
Dermatology
Pim Aarts, Jessie J. Aitken, Kelsey R. van Straalen
Summary: In this study, patients with HS were found to have more than 4 times the odds of having central sensitization compared with age and sex-matched controls. This highlights the importance of actively screening for central sensitization and depressive symptoms in patients with discrepant pain experiences.
Review
Pharmacology & Pharmacy
Dalma Malvaso, Laura Calabrese, Andrea Chiricozzi, Flaminia Antonelli, Giulia Coscarella, Pietro Rubegni, Ketty Peris
Summary: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease that significantly affects patients' quality of life. The current treatment options are limited, creating a need for new therapeutic targets. IL-17 plays a crucial role in the pathogenesis of HS, and biologic agents targeting IL-17 have shown promising results for the treatment of this disease.
Review
Dermatology
Nouf Almuhanna, Alexandra Finstad, Raed Alhusayen
Summary: The study found that HS patients have a 3-fold increased risk of developing inflammatory arthritis. HS patients are specifically at a higher risk for spondyloarthritis, its subtype AS, and RA.
Article
Dermatology
K. T. Savage, E. Gonzalez Brant, K. S. Flood, P. Salian, M. L. Porter, A. B. Kimball
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2020)
Letter
Dermatology
Sandeep Kumar, Kelsey Flood, Nicole M. Golbari, Alexandra P. Charrow, Martina L. Porter, Alexa B. Kimball
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2021)
Letter
Dermatology
Kelsey S. Flood, Martina L. Porter, Alexa B. Kimball
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2021)
Article
Dermatology
N. M. Golbari, J. M. van der Walt, A. Blauvelt, C. Ryan, P. van de Kerkhof, A. B. Kimball
Summary: The study aimed to determine whether the commonly used thresholds to define moderate psoriasis (PASI of 10-12 and BSA of 10) are supported by patient-reported DLQI data. The results indicated that patients with PASI or BSA scores less than 10 can have major quality of life impairment.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2021)
Article
Dermatology
Amit Garg, Neeta Malviya, Andrew Strunk, Shari Wright, Afsaneh Alavi, Raed Alhusayen, Ali Alikhan, Steven D. Daveluy, Isabelle Delorme, Noah Goldfarb, Wayne Gulliver, Iltefat Hamzavi, Tarannum Jaleel, Alexa B. Kimball, Joslyn S. Kirby, Mark G. Kirchhof, Janice Lester, Hadar Lev-Tov, Michelle A. Lowes, Robert Micheletti, Lauren A. Orenstein, Vincent Piguet, Christopher Sayed, Jerry Tan, Haley B. Naik
Summary: This study aims to provide evidence-based screening recommendations for comorbidities associated with HS. Screening recommendations were made based on the consistency and quality of existing studies, disease prevalence and magnitude of association, as well as benefits, harms, and feasibility of screening. A total of 30 comorbidities were recommended for screening in order to improve patients' quality of life and health status.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2022)
Review
Medicine, General & Internal
Stacey A. Missmer, Frank F. Tu, Sanjay K. Agarwal, Charles Chapron, Ahmed M. Soliman, Stephanie Chiuve, Samantha Eichner, Idhaliz Flores-Caldera, Andrew W. Horne, Alexandra B. Kimball, Marc R. Laufer, Nicholas Leyland, Sukhbir S. Singh, Hugh S. Taylor, Sawsan As-Sanie
Summary: Endometriosis can have profound negative impacts on individuals' lives, affecting various aspects such as quality of life, physical health, social activities, and relationships. The disease may lead to difficulties in education, career, relationships, and family formation, ultimately altering one's life trajectory.
INTERNATIONAL JOURNAL OF GENERAL MEDICINE
(2021)
Letter
Dermatology
L. M. Prens, M. L. Porter, K. T. Savage, P. Salian, B. Horvath, A. B. Kimball
BRITISH JOURNAL OF DERMATOLOGY
(2021)
Editorial Material
Dermatology
R. S. Gibson, A. B. Kimball
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2021)
Article
Dermatology
Peyton C. Morss-Walton, Ranch Kimball, Monica Rosales Santillan, Jean S. McGee, Anthony Cukras, Sachin Patwardhan, Martina L. Porter, Alexa B. Kimball
Summary: Swimmers with acne did not experience significant decreases in sebum levels or shine measurements after swimming, while swimmers without acne did. Swimming may remove more superficial sebum, leaving swimmers susceptible to both dry skin and acne simultaneously.
PEDIATRIC DERMATOLOGY
(2022)
Review
Pharmacology & Pharmacy
Stella X. Chen, Charlotte Greif, Ruby S. Gibson, Martina L. Porter, Alexa B. Kimball
Summary: This article reviews the data available from clinical trials and studies on existing and emerging biologic and small molecule inhibitor therapies for the treatment of hidradenitis suppurativa. The biologics discussed include TNF alpha, IL-17, IL-23, IL-12/23, and IL-1 inhibitors, while the small molecule inhibitors discussed include PDE4, JAK, TYK, IFX-1, and complement cascade inhibitors. The pharmacokinetics and pharmacodynamics of these drugs are also described.
EXPERT OPINION ON PHARMACOTHERAPY
(2022)
Letter
Dermatology
C. Greif, M. L. Porter, A. B. Kimball
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2022)
Article
Dermatology
Alexa B. Kimball, Maurizio Podda, Afsaneh Alavi, Megan Miller, Yaung-Kaung Shen, Shu Li, Yan Xu, Chenglong Han, Steven Fakharzadeh, Ya-Wen Yang, Samuel DePrimo, Ernesto Munoz, Yanqing Chen, Thierry Passeron, Kim Papp
Summary: This study aimed to evaluate the effect of guselkumab on the treatment of hidradenitis suppurativa (HS). The results showed that although there were modest improvements in HiSCR in the guselkumab group compared to the placebo group at Week 16, statistical significance was not achieved. Numerically greater improvements in patient-reported outcomes were also observed in the guselkumab group. However, the overall findings do not support the efficacy of guselkumab in the treatment of HS.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2023)
Article
Dermatology
Alexa B. Kimball, Errol P. Prens, Thierry Passeron, Emanual Maverakis, Irina Turchin, Stefan Beeck, Leonidas Drogaris, Ziqian Geng, Tianyu Zhan, Izabella Messina, Falk G. Bechara
Summary: This study evaluated the efficacy and safety of risankizumab in the treatment of moderate-to-severe hidradenitis suppurativa (HS). The results showed that risankizumab is not an effective treatment for moderate-to-severe HS.
DERMATOLOGY AND THERAPY
(2023)
Article
Immunology
Corey L. Snyder, Ruby S. Gibson, Martina L. Porter, Alexa B. Kimball
Summary: Secukinumab, an IL-17A inhibitor, has shown promising results in the treatment of hidradenitis suppurativa. This article reviews its mechanism of action, clinical efficacy, and safety data. Hidradenitis suppurativa is a chronic skin disorder characterized by painful bumps, tunnels, and scarring. Tnf-alpha inhibitor adalimumab is currently the only FDA-approved medication for this condition.
Article
Health Care Sciences & Services
Jennifer P. Stevens, Oren Mechanic, Lawrence Markson, Ashley O'Donoghue, Alexa B. Kimball
Summary: The study found that during the COVID-19 pandemic, the use of telehealth did not exacerbate inequitable access to care. Both Black and White patients accessed telehealth more than Asian patients.
JOURNAL OF MEDICAL INTERNET RESEARCH
(2021)